In this review, we provided an overview of the effects of SGLT2 inhibitors on NAFLD development with a focus on biomarkers that could be useful for early screening of NAFLD in patients with T2DM. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.